Search by Drug Name or NDC
NDC 00169-4307-13 RYBELSUS 7 mg/1 Details
RYBELSUS 7 mg/1
RYBELSUS is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novo Nordisk. The primary component is SEMAGLUTIDE.
MedlinePlus Drug Summary
Semaglutide is used along with a diet and exercise program to control blood sugar levels in adults with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) when other medications did not control the sugar levels well enough. Semaglutide is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Semaglutide is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Semaglutide also works by slowing the movement of food through the stomach. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 00169-4307-13Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Semaglutide
Product Information
NDC | 00169-4307 |
---|---|
Product ID | 0169-4307_fa74bbc6-5386-425e-8d4a-6151795ba57b |
Associated GPIs | 27170070000320 |
GCN Sequence Number | 080229 |
GCN Sequence Number Description | semaglutide TABLET 7 MG ORAL |
HIC3 | C4I |
HIC3 Description | ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST) |
GCN | 46965 |
HICL Sequence Number | 044675 |
HICL Sequence Number Description | SEMAGLUTIDE |
Brand/Generic | Brand |
Proprietary Name | RYBELSUS |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Oral Semaglutide |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 7 |
Active Ingredient Units | mg/1 |
Substance Name | SEMAGLUTIDE |
Labeler Name | Novo Nordisk |
Pharmaceutical Class | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA213051 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00169-4307-13 (00169430713)
NDC Package Code | 0169-4307-13 |
---|---|
Billing NDC | 00169430713 |
Package | 3 BLISTER PACK in 1 CARTON (0169-4307-13) / 10 TABLET in 1 BLISTER PACK (0169-4307-01) |
Marketing Start Date | 2019-09-20 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 31.0751 |
Pricing Unit | EA |
Effective Date | 2024-01-01 |
NDC Description | RYBELSUS 7 MG TABLET |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 4 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |